Reading HAE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HAE free→Reading HAE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HAE free→NYSEHealth CareMedical DevicesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been steady, although the capital stance is capital unfriendly. Risk is elevated, and the sector backdrop is a headwind, with HAE compared to sector peers being above typical. Peer multiples imply a price about 19% above where it trades (it looks cheap on this basis); the read is fair, quality intact. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $78.20. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $78 HAE trades at 17× p/e, below its 20× p/e peer median. Our $95 fair value sits above the price; medium confidence. Analysts: $67–$89. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 18% below a flat-multiple fair value, below our forecast of about 2%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2932.20x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.16 → $1.10 (-5.4% / 30d). 2 raised, 7 cut, 11 covering analysts.
1 upgrade, 0 downgrades / 30d, 1 maintained. 73% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$146.
How much price usually moves either way.
On a bad day, this stock has moved -$314.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,006.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This growth range is key for Haemonetics to meet its fiscal 2027 target. It shows how well the company is expanding its sales.
Confirms:Q1 organic revenue growth reported at 5% or higher.
Disproves:Q1 organic revenue growth was below 3%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for HAE yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 7, 2026, Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 28, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or o…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$67.00 – $89.00 (median $70.00) · 3 analysts · as of 2026-05-12
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
HAE Haemonetics | Above typical Show detailsSector percentile: 93 of 100 | fair | elevated |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 93 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 94 of 100 | fair | elevated |
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Haemonetics aims to achieve organic revenue growth of 3-6% in fiscal 2027.
Haemonetics targets a year-over-year operating margin expansion of 50-100 basis points.
Haemonetics aims to maintain free cash flow conversion at approximately 80%.
Why it matters: A drop in revenue growth would signal weakening demand in a growing sector.
Confirms:Q4 revenue growth reported below 5% year over year.
Disproves:Q4 revenue growth stays above 5% year over year.
Why it matters: Stable leaders help guide the company. Changes can affect how investors feel and plan.
Confirms:A new executive hire was announced. This will make the leadership stronger.
Disproves:More executives are leaving. There are also issues with leadership.
Why it matters: Maintaining cash flow is crucial for funding operations and growth. A drop signals potential financial issues.
Confirms:Free cash flow conversion reported at 80% or higher.
Disproves:Free cash flow conversion reported below 80%.
Why it matters: This margin expansion is important for profitability. It shows how well the company is managing costs.
Confirms:Operating margin expands by 75 bps or more YoY.
Disproves:Operating margin expands less than 50 bps YoY.
Why it matters: A drop in sector revenue growth may show bigger problems for Haemonetics.
Confirms:Sector revenue growth reported below its median year over year.
Disproves:Sector revenue growth remains above its median year over year.
Director — Charles J. Dockendorff: Mr. Dockendorff will not stand for re-election at the 2026 Annual Meeting.